Skip to main content
Home
About
Company Overview
Team
Partners
Careers
Patient Resource
Pipeline
Investors
Newsroom
Contact
Facebook
Twitter
Linkedin
MENU
Home
About
Company Overview
Team
Partners
Careers
Patient Resource
Pipeline
Investors
Newsroom
Contact
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Press Releases
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2020
2019
2018
2017
2016
05/26/2020
Tetra Bio-Pharma Announces Foreign Patent and Reinforces its Ophthalmic IP Portfolio with a New Australian Patent
05/22/2020
Tetra Bio-Pharma Announces Closing of Public Offering
05/15/2020
Two Quebec Companies Joined Forces to Make Healthcare Mask for our "Guardian Angels"
05/15/2020
Deux compagnies Québécoises unissent leurs forces afin de rendre disponible un masque haute performance pour nos Anges Gardiens
05/15/2020
Tetra Bio-Pharma Announces Sizing of Public Offering
05/14/2020
Tetra Bio-Pharma Announces Overnight Marketed Offering
05/13/2020
Tetra Announces Resignation of President
05/11/2020
Tetra Bio-Pharma Provides Update on PPP003 Inflammatory Cytokine Reduction Drug Program
05/11/2020
Tetra Bio-Pharma Obtains Health Canada Approval for Renewal of its Veterinary Clinical Study
05/08/2020
Tetra Bio-Pharma Engages energi PR as its Public Relations Firm
05/06/2020
Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program
04/27/2020
Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome
04/27/2020
Tetra Bio-Pharma annonce qu'un de ces médicaments en recherche a le potentiel d'influencer la gestion du syndrome de libération des cytokine
04/22/2020
Tetra Expands on its Orphan Drug Development Program and Management Update
04/16/2020
Tetra Receives its 4th FDA Orphan Drug Designation
04/15/2020
Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program
04/14/2020
Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License
04/08/2020
Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions
04/06/2020
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011
04/02/2020
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF
04/01/2020
Tetra Bio Pharma Announces Filing of Final Base Shelf Prospectus for up to $50 Million of Securities
03/30/2020
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A
03/26/2020
Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial
03/23/2020
Tetra Bio-Pharma Provides Management Update on COVID-19
03/06/2020
Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm
03/05/2020
Tetra Bio-Pharma Announces Exercise of Over-Allotment Option in Connection with Bought Deal Financing
02/27/2020
Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific
02/25/2020
Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA
02/24/2020
Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA
02/20/2020
Tetra Bio-Pharma Inc. Announces Listing of Warrants
02/20/2020
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs
02/18/2020
Tetra Bio-Pharma Appoints Sylvain Chrétien as President
02/13/2020
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011
02/13/2020
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
02/03/2020
Tetra Bio-Pharma Announces CAUMZ Program Update AND Expansion of Market Potential Following Type B Meeting with USA FDA
01/31/2020
Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™
01/28/2020
Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003
01/27/2020
Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering
01/22/2020
TETRA BIO-PHARMA - PRESS RELEASE CORRECTION
01/21/2020
Tetra Bio-Pharma Announces $10.0 Million Bought Deal Offering
01/20/2020
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs
01/17/2020
Tetra Bio-Pharma Granted Two OTC Drug Identification Numbers (DIN) by Health Canada
01/13/2020
Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF